Detalhe da pesquisa
1.
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
Eur J Neurol
; 31(2): e16131, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37955557
2.
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Cephalalgia
; 43(5): 3331024231170807, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125484
3.
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
Eur J Neurol
; 30(4): 1089-1098, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36583633
4.
Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
J Headache Pain
; 24(1): 155, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37985968
5.
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 22(1): 205, 2022 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659622
6.
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
J Headache Pain
; 23(1): 153, 2022 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460983
7.
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Headache
; 61(1): 125-136, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33314079
8.
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
J Headache Pain
; 22(1): 16, 2021 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33781209
9.
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
Mult Scler
; 24(11): 1469-1484, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28799444
10.
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
BMC Neurol
; 23(1): 318, 2023 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674117
11.
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Br J Clin Pharmacol
; 82(2): 380-8, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060836
12.
Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
J Headache Pain
; 22(1): 46, 2021 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34034644
13.
Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
Neuroepidemiology
; 44(1): 16-23, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25634764
14.
Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.
Neurol Ther
; 13(2): 339-353, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38236314
15.
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet Neurol
; 21(7): 597-607, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35716692
16.
Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease.
Alzheimers Dement (N Y)
; 6(1): e12090, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33083513
17.
Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
Mult Scler J Exp Transl Clin
; 5(1): 2055217318822148, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30729026
18.
Multiple sclerosis patients treated with intramuscular IFN-ß-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Expert Opin Drug Deliv
; 12(1): 15-25, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25430947
19.
Neuron loss after coronary artery bypass detected by SPECT estimation of benzodiazepine receptors.
Ann Thorac Surg
; 74(5): 1576-80, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12440611
20.
Cerebral blood flow and cognitive dysfunction after coronary surgery.
Ann Thorac Surg
; 73(4): 1174-8; discussion 1178-9, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11996259